Clinical trials: Rhinoconjunctivitis
Rhinitis Allergic, Conjunctivitis
A Study of SCH 697243 in Participants With Grass Pollen Allergy Symptoms, With or Without Asthma (P08067)
This is a study to evaluate the efficacy and safety of grass sublingual tablet (SCH 697243) versus placebo in the treatment of grass pollen-induced allergic hayfever symptoms.
- Trial name
- NCT01385371
- Testing
- Grass (Phleum pratense) pollen allergen extract
- Volunteers
- 1,501 people
- Sponsor
- ALK-Abelló A/S
Birch Pollen Allergy
Safety and Efficacy of Recombinant Birch Pollen Allergen in the Treatment of Allergic Rhinoconjunctivitis
Safety and efficacy of recombinant birch pollen allergen in the treatment of allergic rhinoconjunctivitis
- Trial name
- NCT00309062
- Testing
- Recombinant birch pollen
- Where
- Germany
- Sponsor
- Allergopharma GmbH & Co. KG
Rhinoconjunctivitis, Grass Allergy
ToleroMune Grass Follow on Study
Grass pollen allergens are recognised as a major cause of allergic diseases in humans and animals. Worldwide, at least 40% of allergic patients are sensitised to grass pollen allergens and between 50-90% of hayfever or seasonal…
- Trial name
- NCT02292875
- Where
- 2 sites in Canada
- Volunteers
- 84 people
- Sponsor
- Circassia Limited
Allergic Rhinoconjunctivitis
Efficacy-safety Study of Sublingual Immunotherapy With Depigmented-polymerized Pollen Extracts to Treat Rhinoconjunctivitis
As the principal objective of this study is to evaluate the efficacy and safety of the treatment measuring the changes in a symptom score, the patient will be asked to fill in a patient diary.
- Trial name
- GPIT (NCT00550875)
- Testing
- Grass pollen allergenic extract (L. perenne-C. dactylon )
- Where
- South Africa
- Volunteers
- 90 people
- Sponsor
- Laboratorios Leti, S.L.
Rhinoconjunctivitis
Open Label Safety Study of a Birch Pollen Allergen Extract
This trial is performed to assess safety of a sublingual birch pollen extract.
- Trial name
- NCT00818181
- Testing
- Biological: AL0206st
- Where
- Germany
- Volunteers
- 73 people
- Sponsor
- Allergopharma GmbH & Co. KG
Allergic Rhinitis, Allergic Rhinoconjunctivitis
Demonstration of an Anti-allergic Effect in Subjects Treated With Callergin Nasal Spray in Comparison to Untreated Subjects and Subjects Treated With Vis Alpin® Alpensalz Nasal Spray, All Suffering From Grass Pollen Induced Rhinitis/Rhinoconjunctivitis
Allergic rhinitis (AR) in its seasonal and perennial form is a common allergic condition. The majority of allergic rhinitis sufferers report nasal (congestion, sneezing, itching and rhinorrhea) and ocular (redness, watery eyes…
- Trial name
- NCT04531358
- Testing
- nasal spray, no treatment
- Where
- Austria
- Volunteers
- 42 people
- Sponsor
- Marinomed Biotech AG
Seasonal Allergic Rhinitis, Asthma
Study of Grass-SPIRE in Subjects With Grass Allergies and Asthma
The purpose of this study is to determine whether it is safe to administer Grass-SPIRE to subjects suffering from both grass allergy and asthma
- Trial name
- NCT02161107
- Testing
- Grass-SPIRE
- Where
- 5 sites in Canada
- Volunteers
- 54 people
- Sponsor
- Circassia Limited
Allergic Rhinitis, Rhinoconjunctivitis
Efficacy Study of a Preseasonal Treatment With AllerT in Subjects With Birch Pollen Allergy
The main objective of the trial is to demonstrate the efficacy of a two months pre-seasonal treatment with AllerT 100 µg maintenance dose in reducing symptoms of allergic rhinoconjunctivitis during the following birch pollen…
- Trial name
- NCT01720251
- Testing
- AllerT low dose, AllerT full dose
- Where
- 24 sites in Denmark, France and 5 more
- Volunteers
- 240 people
- Sponsor
- Anergis
Rhinoconjunctivitis, Rhinitis
Safety Study of Ragweed Allergy Immunotherapy Tablet in Subjects 50 Years of Age and Older (Study P06081)
The purpose of this study was to assess the safety and tolerability of a ragweed allergy immunotherapy tablet (AIT) administered sublingually (under-the tongue) in subjects 50 years of age and older with ragweed-induced…
- Conditions
- Rhinoconjunctivitis, Rhinitis, Conjunctivitis, Allergy
- Trial name
- NCT00978029
- Testing
- SCH 39641
- Volunteers
- 203 people
- Sponsor
- ALK-Abelló A/S
Allergic Rhinitis, Rhinoconjunctivitis
Evaluation of Tolerability and Safety of "Allergovac Poliplus" in Polysensitized Patients With Rhinitis or Allergic Rhinoconjunctivitis With or Without Asthma: A Study in Daily Clinical Practice
This is an observational prospective study to assess the tolerability and safety of treatment of SCIT Allergovac Poliplus polymerized in depot presentation.
- Conditions
- Allergic Rhinitis, Rhinoconjunctivitis, Asthma
- Trial name
- APOLO (NCT02844842)
- Testing
- Allergovac Poliplus
- Where
- 15 sites in Spain
- Volunteers
- 152 people
- Sponsor
- Roxall Medicina España S.A
Allergy
Efficacy and Safety Trial of SLITone(TM) Birch in Subjects With Hayfever
The trial is performed to assess the efficacy and safety of SLIT One birch for treatment of birch pollen induced allergy
- Trial name
- NCT00310466
- Testing
- Sublingual immunotherapy
- Where
- Germany
- Volunteers
- 226 people
- Sponsor
- ALK-Abelló A/S
Rhinitis, Allergic, Rhinoconjunctivitis
Efficacy and Safety Evaluation for the Treatment of Allergy Against Mites
A double-blinded, placebo-controlled, prospective, multicenter randomized of 2 active treatment groups, compared to 1 placebo group, for the determination of the efficacy and safety of subcutaneous immunotherapy in patients with…
- Conditions
- Rhinitis, Allergic, Rhinoconjunctivitis, Asthma, Allergic
- Trial name
- MM09-SIT-023 (NCT04435990)
- Testing
- 10,000 MM09, 30,000 MM09
- Where
- 32 sites in Spain
- Volunteers
- 150 people
- Sponsor
- Inmunotek S.L.
Rhinitis, Allergic, Rhinoconjunctivitis
Study to Evaluate the Efficacy and Safety of "Allergovac Poliplus" in Polysensitized Patients With Allergic Rhinitis/Rhinoconjunctivitis, With or Without Asthma
This is an observational prospective multicenter clinical study, to evaluate the efficacy and safety of the treatment with Allergovac Poliplus subcutaneous immunotherapy (SCIT) with a mixture of 2 allergenic extracts (pollens or…
- Trial name
- ARES (NCT03821077)
- Testing
- Allergen Immunotherapy (AIT)
- Where
- 10 sites in Spain
- Volunteers
- 122 people
- Sponsor
- Roxall Medicina España S.A
Seasonal Rhinitis and/or Rhinoconjunctivitis, Birch Pollen Allergy
SUBLIVAC® Birch PROBE Study
Objective of the study is to show, on an exploratory basis, that treatment with SUBLIVAC Birch is also effective compared to treatment with Staloral Birch by means of reduction in allergic symptoms during nasal provocation in…
- Trial name
- NCT00932607
- Testing
- sublingual immunotherapy
- Where
- Germany
- Volunteers
- 74 people
- Sponsor
- HAL Allergy
Allergic Rhinitis/Rhinoconjunctivitis +- Intermittent Asthma, Sensitization Against Phleum Pratense Pollen
Dose Finding Study Depigoid Phleum: 4 Doses in Patients With Allergic Rhinitis/Rhinoconjunctivitis +-Asthma
Specific immunotherapy for IgE mediated sensitization to grass pollen 4 concentrations of a modified pollen extract of Phleum pratense are applied to find out the optimum dose.
- Conditions
- Allergic Rhinitis/Rhinoconjunctivitis +- Intermittent Asthma, Sensitization Against Phleum Pratense Pollen, Dose-Finding Study
- Trial name
- NCT01634958
- Testing
- Depigoid Phleum
- Where
- 2 sites in Germany
- Volunteers
- 308 people
- Sponsor
- Leti Pharma GmbH
Rhinitis, Allergic, Seasonal, Conjunctivitis, Allergic
Twin SUBLIVAC® Grasses Clinical Efficacy Study
To show that treatment with SUBLIVAC® Grasses is clinically effective by means of reduction in allergic symptoms and/or use of allergic symptomatic medication in subjects suffering from IgE mediated allergic complaints triggered…
- Trial name
- NCT00422149
- Testing
- SUBLIVAC® Grasses treatment
- Where
- 60 sites in Belgium, Germany and 2 more
- Volunteers
- 350 people
- Sponsor
- HAL Allergy
Grass Pollen Allergy
A Phase III Trial Assessing the Pharmacodynamic Effect and the Tolerability of Grazax Treatment
The study assess the pharmacodynamic effect and the tolerability of Grazax treatment initiated in the grass pollen season in subjects with seasonal grass pollen induced rhinoconjunctivitis
- Trial name
- NCT00773240
- Testing
- Grazax
- Where
- Denmark
- Volunteers
- 276 people
- Sponsor
- ALK-Abelló A/S
Hypersensitivity
Safety and Efficacy of an Allergen Vaccine in Grass-Pollen Allergy
The purpose of this study is to evaluate whether the use of a specific immunomodulatory principle (QbG10) together with conventional grass pollen allergen leads to a more rapid and more pronounced decrease of sensitivity against…
- Trial name
- NCT00293904
- Testing
- CYT005-AllQbG10
- Where
- Switzerland
- Volunteers
- 36 people
- Sponsor
- Cytos Biotechnology AG
Seasonal Allergic Rhinoconjunctivitis
Safety Study of Grass Pollen-derived Peptides to Treat Seasonal Allergic Rhinoconjunctivitis
The purpose of this study is to determine whether the oral administration of grass pollen peptides is safe and effective in the treatment of allergic rhinitis.
- Trial name
- NCT00833066
- Testing
- gpASIT+TM
- Where
- 4 sites in Belgium
- Volunteers
- 54 people
- Sponsor
- BioTech Tools S.A.
Rhinoconjunctivitis
ToleroMune House Dust Mite (HDM) Tolerability Study
House Dust Mites (HDMs) are arachnids that infest bedding, carpet, upholstered furniture and fabric. Like many other allergens, exposure to HDMA in sensitised patients is associated with poorer lung function, greater medication…
- Trial name
- NCT01949441
- Testing
- ToleroMune HDM
- Where
- Canada
- Volunteers
- 30 people
- Sponsor
- Circassia Limited